Reverse-transcriptase inhibitor

Global Antiretroviral Therapy Market (NRTI, NNRTI, Protease Inhibitors & Integrase Inhibitors): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

Saturday, May 23, 2020 - 12:20am

The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.

Key Points: 
  • The global antiretroviral therapy market is also prone to certain challenges like increasing voluntary male circumcisions and huge cost of treatment.
  • The global antiretroviral therapy market by drug type can be segmented into the following: NRTI, NNRTI, protease inhibitors and integrase inhibitors.
  • The global antiretroviral therapy market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
  • The report provides a comprehensive analysis of the global antiretroviral therapy market with potential impact of COVID-19.

Outlook on the Worldwide Anti-viral Drug Industry to 2025 - Major Players and Strategy Analysis - ResearchAndMarkets.com

Wednesday, May 20, 2020 - 2:23pm

The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world.

Key Points: 
  • The global anti-viral drug market is increasing due to the increasing prevalence of influenza across various countries around the world.
  • The increasing influenza prevalence around the world is a second major reason for the increasing demand for anti-viral drugs around the world.
  • On the basis of application type, the global anti-viral drug market is segmented by herpes antiviral drugs, hepatitis antiviral drugs, HIV antiviral drugs, influenza antiviral drugs, and other antiviral drugs.
  • The global anti-viral drug market segmentation based on the mechanism of action is done by nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others.

Technological Advances in the Anti-Viral Drug Therapy Market to Aid Treatment of COVID-19 Patients, Reports TBRC

Thursday, May 14, 2020 - 4:30pm

Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.

Key Points: 
  • Such initiatives and activities are projected to support the anti-viral drug therapy market growth to a significant extent.
  • The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of the anti-viral drugs market.
  • Increasing public-private funding for life science research globally is also expected to drive the growth of the global anti-viral drug therapy market.
  • Request A Free Sample Of The Anti-Viral Drug Therapy Market Report:
    The anti-viral drug therapy market is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.

New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults

Monday, March 9, 2020 - 6:53pm

The use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational.

Key Points: 
  • The use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational.
  • The data presented at CROI 2020 are part of our relentless pursuit to address unmet needs in HIV treatment.
  • The study showed noninferior antiviral efficacy for people switching to Biktarvy from a variety of regimens, including in patients with pre-existing NRTI resistance.
  • The double-blind Phase 3 studies 1489 and 1490 randomized 1274 treatment-nave adults to assess the safety and efficacy of Biktarvy.

Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed

Friday, September 20, 2019 - 11:45am

PIFELTRO (doravirine, 100 mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral agents.

Key Points: 
  • PIFELTRO (doravirine, 100 mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral agents.
  • DELSTRIGO is a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg).
  • In addition, 91% of participants who switched to DELSTRIGO on Day 1 (ISG) had HIV-1 RNA
  • Overall, the safety profile in virologically suppressed adult participants was similar to that in participants with no antiretroviral treatment history.

Global Hepatitis B Market Report 2019 - Key Marketed and Pipeline Drugs, Clinical Trials, Recent Events, Deals

Thursday, June 27, 2019 - 9:45pm

DUBLIN, June 27, 2019 /PRNewswire/ -- The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 27, 2019 /PRNewswire/ -- The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.
  • Marketed drugs for hepatitis B focus on targets such as DNA polymerase, reverse transcriptase, cell membrane, T lymphocytes, immune system, and interferon receptor.
  • Half of the industry-sponsored drugs in active clinical development for hepatitis B are in Phase I, with only one drug in Phase III.
  • GlaxoSmithKline leads the industry sponsors with by far the highest number of clinical trials for hepatitis B, followed by Gilead.

Global Hepatitis B Market Spotlight 2019 - 10 Year Disease Prevalence Forecasts - ResearchAndMarkets.com

Thursday, June 27, 2019 - 11:05am

The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Hepatitis B" report has been added to ResearchAndMarkets.com's offering.
  • Marketed drugs for hepatitis B focus on targets such as DNA polymerase, reverse transcriptase, cell membrane, T lymphocytes, immune system, and interferon receptor.
  • Half of the industry-sponsored drugs in active clinical development for hepatitis B are in Phase I, with only one drug in Phase III.
  • GlaxoSmithKline leads the industry sponsors with by far the highest number of clinical trials for hepatitis B, followed by Gilead.

Global Antiretroviral Market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 - 2023

Wednesday, April 17, 2019 - 9:18pm

The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others).

Key Points: 
  • The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others).
  • However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth.
  • Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017.
  • Global Antiretroviral Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
    Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.

Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance

Wednesday, March 6, 2019 - 10:30pm

The studies found high rates of virologic suppression with Biktarvy in treatment-experienced adults, regardless of pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs).

Key Points: 
  • The studies found high rates of virologic suppression with Biktarvy in treatment-experienced adults, regardless of pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs).
  • Virologically suppressed adults must have no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.
  • All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
  • Biktarvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.